UroGen Pharma Ltd. (URGN)

UroGen Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	84.3	82.71	64.36	48.04	11.8	0.02
Revenue Growth (YoY)	24.00%	28.52%	33.96%	307.17%	65450.00%	-98.40%
Cost of Revenue	8.82	9.36	7.65	5.16	1.01	0
Gross Profit	75.48	73.35	56.7	42.89	10.79	0.02
Selling, General & Admin	96.1	93.27	82.84	87.54	90.22	60.2
Research & Development	48.61	45.61	52.91	47.64	47.31	49.3
Operating Expenses	144.71	138.89	135.74	135.18	137.53	109.5
Operating Income	-69.23	-65.54	-79.04	-92.29	-126.74	-109.48
Interest Expense / Income	13.61	14.72	8.44	0	0	0
Other Expense / Income	17.52	18.07	20.55	17.08	-1.63	-4.33
Pretax Income	-100.36	-98.32	-108.03	-109.37	-125.11	-105.15
Income Tax	3.95	3.92	1.76	1.45	3.37	0
Net Income	-104.32	-102.24	-109.78	-110.82	-128.48	-105.15
Shares Outstanding (Basic)	33	29	23	22	22	21
Shares Outstanding (Diluted)	33	29	23	22	22	21
Shares Change	43.38%	26.43%	2.06%	2.60%	6.10%	30.31%
EPS (Basic)	-3.34	-3.55	-4.81	-4.96	-5.90	-5.12
EPS (Diluted)	-3.34	-3.55	-4.81	-4.96	-5.90	-5.12
Free Cash Flow	-82.48	-76.57	-87.81	-85.64	-107.1	-71.34
Free Cash Flow Per Share	-2.47	-2.66	-3.85	-3.83	-4.92	-3.48
Gross Margin	89.53%	88.68%	88.11%	89.27%	91.45%	100.00%
Operating Margin	-82.12%	-79.23%	-122.82%	-192.11%	-1074.15%	-608211.11%
Profit Margin	-123.74%	-123.61%	-170.58%	-230.67%	-1088.94%	-584144.44%
Free Cash Flow Margin	-97.83%	-92.57%	-136.45%	-178.27%	-907.71%	-396344.44%
EBITDA	-85.13	-81.9	-97.77	-107.6	-123.07	-103.82
EBITDA Margin	-100.99%	-99.02%	-151.92%	-223.97%	-1043.02%	-576788.89%
Depreciation & Amortization	1.62	1.71	1.82	1.77	2.04	1.32
EBIT	-86.76	-83.61	-99.59	-109.37	-125.11	-105.15
EBIT Margin	-102.91%	-101.08%	-154.75%	-227.66%	-1060.34%	-584144.44%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).